The global burden of IBD: from 2015 to 2025, Nat Rev Gastroenterol Hepatol. déc, vol.12, issue.12, pp.720-727, 2015. ,
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology. janv, vol.142, issue.1, pp.46-54, 2012. ,
Genetics versus environment in inflammatory bowel disease: results of a British twin study, BMJ. 13 janv, vol.312, issue.7023, pp.95-101, 1996. ,
Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics, Gastroenterology. juin, vol.124, issue.7, pp.1767-73, 2003. ,
Prevalence of inflammatory bowel disease among relatives of patients with Crohn's disease, Scand J Gastroenterol. mars, vol.26, issue.3, pp.302-308, 1991. ,
Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect, J Crohns Colitis. août, vol.8, issue.8, pp.717-742, 2014. ,
A meta-analysis of the role of smoking in inflammatory bowel disease, Dig Dis Sci. déc, vol.34, issue.12, pp.1841-54, 1989. ,
Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota, Inflamm Bowel Dis. juin, vol.18, issue.6, pp.1092-100, 2012. ,
Current smoking differentially affects blood mononuclear cells from patients with Crohn's disease and ulcerative colitis: relevance to its adverse role in the disease, Inflamm Bowel Dis. juin, vol.18, issue.6, pp.1101-1112, 2012. ,
Passive smoking and inflammatory bowel disease: a meta-analysis, Am J Gastroenterol. sept, vol.103, issue.9, pp.2382-93, 2008. ,
Appendectomy and protection against ulcerative colitis, N Engl J Med. 15 mars, vol.344, issue.11, pp.808-822, 2001. ,
Cultureindependent evaluation of the appendix and rectum microbiomes in children with and without appendicitis, PloS One, vol.9, issue.4, p.95414, 2014. ,
Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease, Clin Exp Immunol. sept, vol.157, issue.3, pp.423-459, 2009. ,
Genomewide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci, Nat Genet. déc, vol.42, issue.12, pp.1118-1143, 2010. ,
NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation, Nat Med. janv, vol.16, issue.1, pp.90-97, 2010. ,
Defects in mucosal immunity leading to Crohn's disease, Immunol Rev. août, vol.206, pp.277-95, 2005. ,
Defects in mucosal immunity leading to ulcerative colitis, Immunol Rev. août, vol.206, pp.296-305, 2005. ,
Nonclassical CD1drestricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis, J Clin Invest. mai, vol.113, issue.10, pp.1490-1497, 2004. ,
The intestinal microbiota in inflammatory bowel diseases: time to connect with the host, Curr Opin Gastroenterol. juill, vol.26, issue.4, pp.327-358, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00599080
Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans, Science. 20 mai, vol.332, issue.6032, pp.970-974, 2011. ,
Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation, Proc Natl Acad Sci U S A. 15 mars, vol.108, issue.1, pp.4554-61, 2011. ,
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease, Gastroenterology. déc, vol.115, issue.6, pp.1405-1418, 1998. ,
Fungal microbiota dysbiosis in IBD, Gut. juin, vol.66, issue.6, pp.1039-1087, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01270909
,
, Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial, Lancet Lond Engl. 25 mars, vol.389, pp.1218-1246, 2017.
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis, J Crohns Colitis. févr, vol.4, issue.1, pp.7-27, 2010. ,
Crohn's disease, Lancet Lond Engl. 29 avr, vol.389, pp.1741-55, 2017. ,
The spectrum of perianal Crohn's disease in a population-based cohort, Dis Colon Rectum. juill, vol.55, issue.7, pp.773-780, 2012. ,
AntiSaccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families, Inflamm Bowel Dis. févr, vol.7, issue.1, pp.8-15, 2001. ,
Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease, Gastroenterology. mars, vol.120, issue.4, pp.827-860, 2001. ,
Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease, Am J Gastroenterol. oct, vol.101, issue.10, pp.2410-2432, 2006. ,
A meta-analysis of the utility of Creactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS, Am J Gastroenterol. mars, vol.110, issue.3, pp.444-54, 2015. ,
Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease, Scand J Gastroenterol, vol.50, issue.9, pp.1183-1187, 2015. ,
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease, Inflamm Bowel Dis. déc, vol.18, issue.12, pp.2218-2242, 2012. ,
Frequency of epithelioid granulomas in colonoscopic biopsy specimens from paediatric and adult patients with Crohn's colitis, J Clin Pathol, vol.60, issue.11, pp.1268-72, 2007. ,
Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease, Aliment Pharmacol Ther. juill, vol.34, issue.2, pp.125-170, 2011. ,
Long-term evolution of disease behavior of Crohn's disease, Inflamm Bowel Dis. juill, vol.8, issue.4, pp.244-50, 2002. ,
The natural history of adult Crohn's disease in population-based cohorts, Am J Gastroenterol. févr, vol.105, issue.2, pp.289-97, 2010. ,
Impact of inflammatory bowel disease on quality of life: Results of the ,
, European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey, J Crohns Colitis. sept, vol.1, issue.1, pp.10-20, 2007.
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease, Gut. déc, vol.49, issue.6, pp.777-82, 2001. ,
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. avr, vol.122, issue.4, pp.875-80, 2002. ,
Clinical risk factors for complicated disease: how reliable are they? Dig Dis Basel Switz, vol.30, pp.67-72, 2012. ,
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut. juin, vol.55, issue.6, pp.749-53, 2006. ,
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology, Can J Gastroenterol J Can Gastroenterol. sept, vol.19, 2005. ,
Epidemiology and natural history of inflammatory bowel diseases, Gastroenterology. mai, vol.140, issue.6, pp.1785-94, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00631553
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis, J Crohns Colitis. déc, vol.6, issue.10, pp.965-90, 2012. ,
The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases, Nat Clin Pract Gastroenterol Hepatol. déc, vol.2, issue.12, pp.580-586, 2005. ,
Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most, J Clin Gastroenterol. févr, vol.10, issue.1, pp.41-46, 1988. ,
Histological predictors of relapse in ulcerative colitis, Abstract OP056, 2017. ,
Risk factors and characteristics of extent progression in ulcerative colitis, Inflamm Bowel Dis. sept, vol.15, issue.9, pp.1320-1325, 2009. ,
Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease, J Crohns Colitis. août, vol.10, issue.8, pp.989-97, 2016. ,
A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, N Engl J Med, vol.337, issue.15, pp.1029-1064, 1997. ,
,
, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, Lancet Lond Engl. 4 mai, vol.359, issue.9317, pp.1541-1550, 2002.
Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med. 8 déc, vol.353, issue.23, pp.2462-76, 2005. ,
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology. janv, vol.146, issue.1, pp.85-95, 2014. ,
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. juin, vol.6, issue.6, pp.644-53, 2008. ,
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT TM registry, Am J Gastroenterol. sept, vol.107, issue.9, pp.1409-1431, 2012. ,
Opportunistic infections with anti-tumor necrosis factor-? therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials, Am J Gastroenterol. août, vol.108, issue.8, pp.1268-76, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01706703
Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases, Aliment Pharmacol Ther, vol.45, issue.1, pp.37-49, 2009. ,
Algorithmes de prise en charge de la rectocolite hémorragique 2015 : Consensus National Français, Hépato Gastro, vol.23, pp.33-42, 2016. ,
Algorithmes de prise en charge de la maladie de Crohn en 2016 : Consensus National Français, Hépato Gastro, vol.23, pp.619-633, 2016. ,
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet Lond Engl. 23 févr, vol.371, issue.9613, pp.660-667, 2008. ,
,
, Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med. 15 avr, vol.362, issue.15, pp.1383-95, 2010.
Cancers Complicating Inflammatory Bowel Disease, N Engl J Med. 9 juill, vol.373, issue.2, p.195, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01301711
,
, Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, Am J Gastroenterol. sept, vol.110, issue.9, pp.1324-1362, 2015.
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease, J Crohns Colitis, vol.5, issue.5, pp.477-83, 2011. ,
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial, Lancet Lond Engl, vol.23, pp.2779-89, 2018. ,
Long-term costeffectiveness of tight control for Crohn, Abstract DOP065, 2018. ,
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects, J Crohns Colitis, vol.4, issue.4, pp.355-66, 2010. ,
Optimizing anti-TNF treatments in inflammatory bowel disease, Autoimmun Rev. janv, vol.13, issue.1, pp.24-30, 2014. ,
Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review, Am J Gastroenterol. mars, vol.104, issue.3, pp.760-767, 2009. ,
Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review, Am J Gastroenterol. avr, vol.106, issue.4, pp.674-84, 2011. ,
Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience, Inflamm Bowel Dis. janv, vol.17, issue.1, pp.152-161, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01732435
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.4, issue.10, pp.1248-54, 2006. ,
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis, Gastroenterology. déc, vol.147, issue.6, pp.1296-1307, 2014. ,
Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases, Am J Gastroenterol. août, vol.109, issue.8, pp.1250-1256, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01688079
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut, vol.64, pp.1539-1584, 2015. ,
Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.10, issue.10, pp.85-86, 2012. ,
Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. janv, vol.12, issue.1, pp.80-84, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01687260
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease, Am J Gastroenterol. mai, vol.105, issue.5, pp.1133-1142, 2010. ,
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial, J Pediatr Gastroenterol Nutr. févr, vol.132, issue.2, pp.226-233, 2007. ,
Review article: loss of response to anti-TNF treatments in Crohn's disease, Aliment Pharmacol Ther. mai, vol.33, issue.9, pp.987-95, 2011. ,
Infliximab dose intensification in Crohn's disease, Inflamm Bowel Dis. sept, vol.13, issue.9, pp.1093-1102, 2007. ,
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease, Inflamm Bowel Dis. juill, vol.18, issue.7, pp.1199-206, 2012. ,
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, N Engl J Med. 13 févr, vol.348, issue.7, pp.601-609, 2003. ,
Antibody response to infliximab and its impact on pharmacokinetics can be transient, Am J Gastroenterol. juin, vol.108, issue.6, pp.962-71, 2013. ,
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab, Gut. août, vol.63, issue.8, pp.1258-64, 2014. ,
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, N Engl J Med. 13 févr, vol.348, issue.7, pp.601-609, 2003. ,
Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease, Aliment Pharmacol Ther, vol.45, issue.8, pp.1128-1162, 2017. ,
Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience, J Crohns Colitis. mai, vol.10, issue.5, pp.516-540, 2016. ,
Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. avr, vol.11, issue.4, pp.444-451, 2013. ,
Addition of an immunomodulator as a rescue therapy for loss of response to adalimumab dose escalation in patients with Crohn's disease, J Crohns Colitis. juill, vol.9, issue.7, pp.589-90, 2015. ,
Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab, Aliment Pharmacol Ther, vol.30, issue.10, pp.977-86, 2009. ,
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin, N Engl J Med. 16 juin, vol.352, issue.24, pp.2499-507, 2005. ,
Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue, Am J Pathol. juill, vol.151, issue.1, pp.97-110, 1997. ,
Vedolizumab as induction and maintenance therapy for Crohn's disease, N Engl J Med. 22 août, vol.369, issue.8, pp.711-732, 2013. ,
Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med. 22 août, vol.369, issue.8, pp.699-710, 2013. ,
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed, Gastroenterology. sept, vol.147, issue.3, pp.618-627, 2014. ,
A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn, Abstract OP023, 2018. ,
,
, Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis, J Crohns Colitis. 1 sept, vol.11, issue.9, pp.1085-1094, 2017.
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.14, issue.11, pp.1593-1601, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01278611
Natalizumab induction and maintenance therapy for Crohn's disease, N Engl J Med, vol.353, issue.18, pp.1912-1937, 2005. ,
The safety of vedolizumab for ulcerative colitis and Crohn's disease, Gut. mai, vol.66, issue.5, pp.839-51, 2017. ,
Long-term Efficacy of Vedolizumab for Ulcerative Colitis, J Crohns Colitis. 1 avr, vol.11, issue.4, pp.400-411, 2017. ,
Long-term Efficacy of Vedolizumab for Crohn's Disease, J Crohns Colitis. 1 avr, vol.11, issue.4, pp.412-436, 2017. ,
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease, Aliment Pharmacol Ther. juill, vol.42, issue.2, pp.188-202, 2015. ,
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease, J Crohns Colitis. 1 août, vol.11, issue.8, pp.921-930, 2017. ,
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.15, issue.11, pp.1750-1757, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01908856
Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study, Aliment Pharmacol Ther. 31 janv, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01720723
Assessing Labeling Claims for Drug Interactions using a Population PK Approach: Vedolizumab. ACOP5 Abstract, 2017. ,
Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity scorematched analysis. DOP053 Abstract, 2018. ,
Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study, Inflamm Bowel Dis. août, vol.18, issue.8, pp.1470-1479, 2012. ,
Association of Vedolizumab Level, Anti-drug Antibodies, and ?4?7 Occupancy With Response in Patients With Inflammatory Bowel Diseases, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 6 déc, 2017. ,
Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers, J Crohns Colitis. août, vol.5, issue.4, pp.301-317, 2011. ,
Biologic agents for IBD: practical insights, Nat Rev Gastroenterol Hepatol. sept, vol.12, issue.9, pp.537-582, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01667747
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF? therapy: results from the COIN study, Gut. janv, vol.63, issue.1, pp.72-81, 2014. ,
Costeffectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom, Eur J Health Econ HEPAC Health Econ Prev Care. 8 mars, 2017. ,
Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis, BMJ Open Gastroenterol, vol.3, issue.1, p.93, 2016. ,
Ustekinumab induction and maintenance therapy in refractory Crohn's disease, N Engl J Med, vol.367, issue.16, pp.1519-1547, 2012. ,
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease, N Engl J Med, vol.17, issue.20, pp.1946-60, 2016. ,
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis, N Engl J Med, vol.04, issue.18, pp.1723-1759, 2017. ,
addition of methotrexate neither restores clinical response nor improve the pharmacokinetic profile of vedolizumab ,
Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease, Aliment Pharmacol Ther, vol.45, pp.1128-1134, 2017. ,
Anti TNF monotherapy for Crohn's disease : a 13year Multicentre Experience, J Crohns Colitis, vol.10, pp.516-540, 2016. ,
Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease, Clin Gastroenterol Hepatol, vol.11, pp.444-447, 2013. ,
Addition of an immunomodulator as a rescue therapy for loss of response to adalimumab dose escalation in patients with Crohn's disease, J Crohn's Colitis, vol.10, pp.589-590, 2015. ,
Vedolizumab as induction and maintenance therapy for Crohn's disease, N Engl J Med, vol.369, pp.711-732, 2013. ,
Early changes in the pharmacokinetic profile of vedolizumab-treated patients with inflammatory bowel disease may predict response after dose optimization ,
The safety of vedolizumab for ulcerative colitis and Crohn's disease, Gut, vol.66, pp.839-51, 2017. ,
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease, J Crohns Colitis, vol.11, pp.921-930, 2017. ,
DOI : 10.1093/ecco-jcc/jjx021
Long-term Efficacy of Vedolizumab for Ulcerative Colitis, J Crohns Colitis, vol.11, pp.400-411, 2017. ,
DOI : 10.1093/ecco-jcc/jjw177
URL : https://academic.oup.com/ecco-jcc/article-pdf/11/4/400/17682347/jjw177.pdf
Long-term Efficacy of Vedolizumab for Crohn's Disease, J Crohns Colitis, vol.11, pp.412-436, 2017. ,
DOI : 10.1093/ecco-jcc/jjw176
URL : https://academic.oup.com/ecco-jcc/article-pdf/11/4/412/17682337/jjw176.pdf